Ocera Therapeutics Inc (NASDAQ:OCRX) has earned an average recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $4.19.

OCRX has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of Ocera Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. HC Wainwright downgraded shares of Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price objective for the company. in a report on Friday, November 3rd. Finally, Cowen reaffirmed a “buy” rating and set a $11.00 price objective on shares of Ocera Therapeutics in a report on Monday, December 18th.

Ocera Therapeutics (OCRX) traded up $0.02 during midday trading on Friday, reaching $1.79. 969,300 shares of the company’s stock traded hands, compared to its average volume of 1,105,401. The firm has a market cap of $47.46, a price-to-earnings ratio of -1.85 and a beta of 2.46. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $2.95.

Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). equities research analysts forecast that Ocera Therapeutics will post -0.93 earnings per share for the current year.

A hedge fund recently raised its stake in Ocera Therapeutics stock. Hikari Power Ltd lifted its holdings in shares of Ocera Therapeutics Inc (NASDAQ:OCRX) by 79.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 676,596 shares of the biopharmaceutical company’s stock after acquiring an additional 300,000 shares during the period. Hikari Power Ltd owned approximately 2.55% of Ocera Therapeutics worth $771,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 17.69% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/12/ocera-therapeutics-inc-ocrx-given-consensus-rating-of-hold-by-analysts.html.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Analyst Recommendations for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Ratings for Ocera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.